CBER/CDER Merger Is One Topic Of Erbitux Discussions In House Cmte.

The House Energy & Commerce Committee investigation of the Erbitux review could re-energize proposals to combine FDA's drugs and biologics centers

More from Archive

More from Pink Sheet